VistaGen Therapeutics, Inc.
General ticker "VTGN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $67.7M (TTM average)
VistaGen Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -22.4%.
Estimated limits based on current volatility of 2.1%: low 0.23$, high 0.25$
Factors to consider:
- Total employees count: 41 (-25.5%) as of 2026
- Top business risk factors: Clinical trial failure, Regulatory and compliance, No approved products, Need substantial capital, Market competition
- Current price 22.1% below estimated low
- Earnings for 3 months up through Q1 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2026-03-31 to 2028-03-30
- 2026-03-31 to 2027-03-31 estimated range: [0.30$, 1.27$]
- 2027-03-31 to 2028-03-30 estimated range: [0.25$, 0.98$]
Financial Metrics affecting the VTGN estimates:
- Positive: with PPE of -0.3 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Positive: -4.49 < Investing cash flow per share per price, % of -3.88
- Positive: 69.38 < Shareholder equity ratio, % of 73.14 <= 81.92
Short-term VTGN quotes
Long-term VTGN plot with estimates
Financial data
| YTD | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|
| Operating Revenue | $1.06MM | $0.49MM | $1.27MM |
| Operating Expenses | $34.09MM | $56.46MM | $73.39MM |
| Operating Income | $-33.02MM | $-55.97MM | $-72.13MM |
| Non-Operating Income | $3.66MM | $4.56MM | $2.45MM |
| R&D Expense | $20.02MM | $39.38MM | $54.97MM |
| Income(Loss) | $-29.36MM | $-51.41MM | $-69.68MM |
| Taxes | $0.00MM | $0.01MM | $0.01MM |
| Net Income(Loss)* | $-29.36MM | $-51.42MM | $-69.69MM |
| Stockholders Equity | $114.29MM | $70.39MM | $35.52MM |
| Assets | $123.65MM | $84.34MM | $48.56MM |
| Operating Cash Flow | $-25.81MM | $-42.10MM | $-66.44MM |
| Capital expenditure | $0.06MM | $0.19MM | $0.15MM |
| Investing Cash Flow | $-0.06MM | $-13.15MM | $-0.88MM |
| Financing Cash Flow | $128.40MM | $3.21MM | $30.97MM |
| Earnings Per Share** | $-1.52 | $-1.67 | $-1.83 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.